Abstract Library

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors

Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Peiró I, Vercher-Conejero J, Suils-Ramón J, Hernández L, Teulé A,

Keywords: 68Ga-DOTATOC PET/CT, metastatic neuroendocrine tumors,

#2931 One-Stage Middle-Preserving Pancreatectomy: Indications and Outcomes

Introduction: Parenchyma-sparing surgical techniques are used in pancreatic surgery to preserve organ function. Middle-preserving pancreatectomy (MPP) may be an alternative to total pancreatectomy (TP) in benign/borderline disease that does not affect pancreatic body.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Milanetto A, David A, Fassan M, Pasquali C,

Keywords: one-stage middle preserving pancreatectomy, parenchyma-sparing pancreatic surgery,

#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis

Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Masui T, Anazawa T, Nagai K, Sato A, Nakano K,

Keywords: liver metastasis, PanNEN, resection, indication,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,